{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:47:39Z","timestamp":1788583659260,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.semcancer.2020.01.001","type":"journal-article","created":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T21:41:41Z","timestamp":1578260501000},"page":"114-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance"],"prefix":"10.1016","volume":"65","author":[{"given":"Kelly","family":"Olino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristen","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2020.01.001_bib0005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0010","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0020","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0025","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 Blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0030","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0040","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0045","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013Positive Non\u2013Small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell Non\u2013Small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le DT","year":"2017","journal-title":"Science (80-)"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0065","first-page":"1","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or Non\u2013Small cell lung cancer treated with nivolumab","author":"Topalian","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0070","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"Paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-med-111314-035900","article-title":"Epigenetic therapeutics: a New weapon in the war against cancer","volume":"67","author":"Ahuja","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0085","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.molcel.2016.05.004","article-title":"Greater than the sum of parts: complexity of the dynamic epigenome","volume":"62","author":"Soshnev","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0090","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrg.2016.93","article-title":"Targeting the cancer epigenome for therapy","volume":"17","author":"Jones","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI69736","article-title":"Harnessing the potential of epigenetic therapy to target solid tumors find the latest version : review series harnessing the potential of epigenetic therapy to target solid tumors","volume":"124","author":"Ahuja","year":"2014","journal-title":"J Clin Invest."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0110","article-title":"Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise","volume":"5","author":"Morel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0115","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0120","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00262-006-0164-4","article-title":"Epigenetic regulation of immune escape genes in cancer","volume":"55","author":"Tomasi","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0125","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of non-small cell lung cancer with azacytidine","volume":"4","author":"Wrangle","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","article-title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0135","article-title":"Guadecitabine plus ipilimumab in unresectable melanoma : the NIBIT-M4 clinical trial","author":"Di Giacomo","year":"2019","journal-title":"Clinical Trials: Immunotherapy"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0140","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-17-1178","article-title":"Immunomodulation by entinostat in renal cell carcinoma patients receiving High-dose interleukin 2: a multicenter, single-Arm, phase I\/II trial (NCI-CTEP#7870)","volume":"23","author":"Pili","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0145","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jcp.10290","article-title":"MHC class I antigens, immune surveillance, and tumor immune escape","volume":"195","author":"Garcia-Lora","year":"2003","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0150","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0155","doi-asserted-by":"crossref","first-page":"9601","DOI":"10.1158\/0008-5472.CAN-07-5270","article-title":"Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors","volume":"68","author":"Setiadi","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179501","article-title":"Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells","volume":"12","author":"Siebenkas","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0165","first-page":"1","article-title":"DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0170","first-page":"1","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0175","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0180","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/0008-5472.CAN-18-3704","article-title":"Epigenomic reordering induced by polycomb loss drives oncogenesis but leads to therapeutic vulnerabilities in malignant peripheral nerve sheath tumors","volume":"79","author":"Wojcik","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0185","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","article-title":"Epigenetic therapy in immune-oncology","volume":"19","author":"Jones","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0190","article-title":"Initial sequencing and analysis of the human genome International human genome sequencing Consortium* the sanger Centre: Beijing genomics Institute\/human genome center","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0195","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0200","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41591-018-0116-5","article-title":"Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses","volume":"24","author":"Ca\u00f1adas","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0205","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2015.00588","article-title":"Molecular and translational classifications of DAMPs in immunogenic cell death","volume":"6","author":"Garg","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0215","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121522","article-title":"Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma","volume":"3","author":"Panda","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0220","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1172\/JCI121476","article-title":"Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma","volume":"128","author":"Smith","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0225","first-page":"1","article-title":"The cancer\/testis genes: review, standardization, and commentary","volume":"4","author":"Scanlan","year":"2004","journal-title":"Cancer Immun"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0230","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1038\/sj.onc.1209678","article-title":"Epigenetic regulation of X-linked cancer\/germline antigen genes by DNMT1 and DNMT3b","volume":"25","author":"James","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0235","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0240","first-page":"11","article-title":"Expression of the cancer\/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors","volume":"7","author":"Velazquez","year":"2007","journal-title":"Cancer Immun"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0245","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.humpath.2013.05.029","article-title":"Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma","volume":"45","author":"Aung","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0250","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00464-012-2269-5","article-title":"Plasma levels of angiopoietin-like protein 4 (ANGPTL4) are significantly lower preoperatively in colorectal cancer patients than in cancer-free patients and are further decreased during the first month after minimally invasive colorectal resection","volume":"26","author":"Shantha Kumara","year":"2012","journal-title":"Surg Endosc"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000101","article-title":"Expression of MAGE-a and NY-ESO-1 in primary and metastatic cancers","volume":"39","author":"Park","year":"2016","journal-title":"J. Immunother."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0260","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/CJI.0000000000000119","article-title":"MAGE-a is more highly expressed than NY-ESO-1 in a systematic immunohistochemical analysis of 3668 cases","volume":"39","author":"Kerkar","year":"2016","journal-title":"J. Immunother."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0265","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/14712598.2016.1161752","article-title":"Prospect and progress of personalized peptide vaccinations for advanced cancers","volume":"16","author":"Sakamoto","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0270","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0275","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","article-title":"Treatment of patients with metastatic cancer using a Major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3","volume":"35","author":"Lu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012994","article-title":"Equitoxic doses of 5-azacytidine and 5-aza-2\u2019deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome","volume":"5","author":"Qiu","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0285","first-page":"1766","article-title":"Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2019-deoxycytidine","volume":"54","author":"Weber","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0290","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1541-7786.MCR-08-0400","article-title":"Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP","volume":"7","author":"Karpf","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0295","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1128\/MCB.24.11.4781-4790.2004","article-title":"Promoter-dependent mechanism leading to selective hypomethylation within the 5\u2019 region of gene MAGE-A1 in tumor cells","volume":"24","author":"De Smet","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0300","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ccr.2004.06.023","article-title":"Preferential response of cancer cells to zebularine","volume":"6","author":"Cheng","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0305","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0310","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0315","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/15592294.2015.1017198","article-title":"Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts","volume":"10","author":"Srivastava","year":"2015","journal-title":"Epigenetics"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0320","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.leukres.2014.09.001","article-title":"Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts","volume":"38","author":"Srivastava","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0179501","article-title":"Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells","volume":"12","author":"Siebenk\u00e4s","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0330","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0335","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0340","doi-asserted-by":"crossref","first-page":"P267","DOI":"10.1186\/2051-1426-2-S3-P267","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"2","author":"Kim","year":"2014","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0345","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.molimm.2014.02.019","article-title":"Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells","volume":"60","author":"Cheng","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0350","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ni.1673","article-title":"The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance","volume":"10","author":"Villagra","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0355","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1038\/s41598-019-42237-3","article-title":"Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells","volume":"9","author":"Knox","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0360","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0365","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0370","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0375","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0380","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.molimm.2017.04.012","article-title":"Epigenetics and immunotherapy: the current state of play","volume":"87","author":"Dunn","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0385","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","article-title":"Combining epigenetic and immunotherapy to combat cancer","volume":"76","author":"Chiappinelli","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0390","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/imr.12174","article-title":"Genetic and epigenetic basis of treg cell development and function: from a FoxP3-centered view to an epigenome-defined view of natural treg cells","volume":"259","author":"Morikawa","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0395","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0400","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.4049\/jimmunol.0800997","article-title":"Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion","volume":"182","author":"Bucks","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0405","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1371\/journal.pmed.0050100","article-title":"Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells","volume":"5","author":"Streeck","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0410","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0415","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0420","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coi.2010.02.013","article-title":"Inflammatory cytokines as a third signal for T cell activation","volume":"22","author":"Curtsinger","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0425","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.1235214","article-title":"Persistent LCMV infection is controlled by blockade of type I interferon signaling","volume":"340","author":"Teijaro","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0430","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.1235208","article-title":"Blockade of chronic type I interferon signaling to control persistent LCMV infection","volume":"340","author":"Wilson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0435","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0440","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0445","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0450","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0455","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0460","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0465","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0470","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41590-019-0403-4","article-title":"Single-cell RNA-seq reveals TOX as a key regulator of CD8(+) T cell persistence in chronic infection","volume":"20","author":"Yao","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0475","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2020.01.001_bib0480","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1172\/JCI86437","article-title":"BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models","volume":"126","author":"Kagoya","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2020.01.001_bib0485","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nature20165","article-title":"S-2-hydroxyglutarate regulates CD8 + T-lymphocyte fate","volume":"540","author":"Tyrakis","year":"2016","journal-title":"Nature"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X2030002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X2030002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:36:07Z","timestamp":1760916967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X2030002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":97,"alternative-id":["S1044579X2030002X"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.01.001","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}